A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting side effect, with WBC counts of <2×109/l being observed in 42% of patients, resulting in one septic death. At the dose and schedule used in the present study, teniposide showed only limited activity in adenocarcinoma of the lung.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bhuchar VK, Boyle LE, Lanzotti VJ (1978) VM-26 in non-oat-cell bronchogenic carcinoma. Proc Am Assoc Cancer Res ASCO 19: 407
Creech RH, Mehta CR, Cohen M, Donovan M, Sponzo R, Mason BA, Skeel RT, Ahmed F, Creaven PJ, Lerner HJ, Foelsch E (1981) Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small-cell lung carcinoma (EST-2575, generation 1). Cancer Treat Rep 65: 431–438
Eagan RT, Frytak S, Creagan ET, Richardson RL, Coles DT, Jett JR (1986) Differing response rates and survival between squamous and non-squamous non-small-cell lung cancer. Am J Clin Oncol 9: 249–254
Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 4: 702–709
Giaccone G, Donadio M, Ferrati P, Bonardi G, Ciuffreda L, Bagatella M, Calciati A (1987) Teniposide in the treatment of non-small-cell lung carcinoma. Cancer Treat Rep 71: 83–85
Madejewicz S, West CR, Park HD (1981) Phase II study of intraarterial 4′-0-demethyl-1-0(4,6-0-2-thenylidene-β-d-glucopyranosyl) epipodophyllotoxin (VM-26) therapy of metastatic bronchogenic adenocarcinoma of the brain. Proc Am Assoc Cancer Res/ASCO 22: 502
Maroun JA, Stewart DJ, Young V, Belanger R, Crook AF (1982) Effectiveness of VM-26 in non-small-cell carcinoma of the lung (NSCLC) with cerebral nervous system (CNS) metastases. Preliminary results. Proc ASCO 1: 140
Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Ewans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer. Report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633–641
Samson MK, Baker LH, Talley RW, Fraile RJ (1978) VM-26 (NSL-122819): a clinical study in advanced cancer of the lung and ovary. Eur J Cancer 14: 1395–1399
Sørensen JB, Hansen HH (1988) Combination chemotherapy for advanced adenocarcinoma of the lung. Cancer Chemother Pharmacol 21: 103–116
Sørensen JB, Clerici M, Hansen HH (1988) Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review. Cancer Chemother Pharmacol 21: 89–102
Sørensen JB, Badsberg JM, Olsen JE (1989) Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate analysis of 259 consecutive patients. Cancer Res 49: 5748–5754
Watkin SW (1989) Temporal demographic and epidemiological variation in histologic subtypes of lung cancer: a literature review. Lung Cancer 5: 69–81
World Health Organization (1979) Handbook for reporting results of cancer treatment. Offset publication 42. WHO, Geneva
About this article
Cite this article
Sørensen, J.B., Bach, F., Dombernowsky, P. et al. Phase II study of teniposide in adenocarcinoma of the lung. Cancer Chemother. Pharmacol. 27, 487–489 (1991). https://doi.org/10.1007/BF00685166
- Cancer Research
- Partial Response
- Evaluable Patient
- Limited Activity